The Critical Medicines Act (CMA) is an opportunity to address Europe’s medicine shortages, particularly for patients relying on plasma-derived therapies. It must ensure resilient plasma supply chains, patient-centred procurement, balanced stockpiling, and support access to innovative treatments like gene therapy.